This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Compound Screening Remove Disease Remove Pharma Companies Related Topics
Small Molecule Drug Development Therapies FDA Approval Clinical Development Licensing Trials Treatment Marketing Research More Related Topics >
article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Several of the large pharma companies have recently re-entered the dementia field.

Disease 130
Disease Small Molecule Compound Screening Clinical Development 130
article thumbnail

What to expect from drug discovery and development in 2023

Drug Discovery World

JANUARY 26, 2023

As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2% They will allow us to treat a disease with one single dose.

Clinical Trials 246
Clinical Trials Drugs Trials Therapies 246
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 42,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024